Results 141 to 150 of about 1,816 (169)
Lancet, The, 2014 International audienceBackgroundAn unmet need exists for interferon-free and ribavirin-free treatments for chronic hepatitis C virus (HCV) infection. In this study, we assessed all-oral therapy with daclatasvir (NS5A replication complex inhibitor) plus ...
Michael P Manns +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Journal of Gastroenterology and Hepatology (Australia), 2016 Background and Aim: Daclatasvir plus asunaprevir has demonstrated efficacy and safety in patients with chronic hepatitis C virus genotype 1b infection. This study focused on evaluating daclatasvir plus asunaprevir in interferon (+/- ribavirin)-ineligible
Mingxiang Zhang +2 more
exaly +2 more sources
Asunaprevir for hepatitis C: a safety evaluation
Expert Opinion on Drug Safety, 2015The introduction of direct-acting antiviral (DAA) agents has revolutionized the treatment of hepatitis C virus (HCV) chronic infection. Non-structural 3 protease inhibitors are currently the most numerous class of DAAs on the market.This review mainly focuses on the tolerability and safety profile of asunaprevir (ASV)-containing DAA regimens.
GENTILE, Ivan +4 more
openaire +3 more sources